Miastenia Gravis Okular Juvenil: Laporan Kasus

https://doi.org/10.35912/jimi.v1i1.592
Published: Sep 20, 2021

Abstract:

Purpose: This study aimed to summarize the general history, physical exam findings, confirmation test, and treatment of a patient with juvenile ocular myasthenia gravis.

Research Methodology: This article is a pediatric RSUD Abdoel Moeloek Lampung case report in April 2021. The subject of the case is a 3-year-old girl who is hospitalized in the hospital ward with juvenile ocular myasthenia gravis.

Result: A 3-year-old girl, an inpatient in the Pediatric Ward, RSUD Abdoel Moeloek Lampung, with complaints of decreased left upper eyelid since three months ago. On physical examination, there was ptosis of the left superior palpebra. Prostigmine test was performed on day 2 of treatment in patients with positive test results. The patient was clinically diagnosed with “Juvenile Ocular Myasthenia Gravis.” Management of the patient during treatment was the injection of methylprednisolone 10 mg/12 hours and neostigmine orally 2.5 mg/8 hours.

Limitations: This case report is limited to juvenile ocular myasthenia gravis cases with a scarce number of cases and rare cases in children.

Contribution: This case report can be helpful in medical education or used as a reference in making relevant case reports and can be applied in the hospital area when there are cases of juvenile ocular myasthenia gravis.

Keywords:
1. Juvenile Ocular Myasthenia Gravis
2. Rare Disease
3. Neuromuscular Junction
4. Muscle Weakness
5. Ptosis
Authors:
Fikta Zakia Nurfaizah
View PDF
How to Cite
Nurfaizah, F. Z. (2021). Miastenia Gravis Okular Juvenil: Laporan Kasus. Jurnal Ilmu Medis Indonesia, 1(1), 39–52. https://doi.org/10.35912/jimi.v1i1.592
Download Citation
  1. Endnote/Zotero/Mendeley (RIS)
  2. BibTeX

Downloads

Download data is not yet available.
Issue & Section
Vol. 1 No. 1 (2021): September
Articles
References

    Alami, Z., Agier, M.S., Ahid, S., Vial, T., Dautriche, A., Lagarce, L., et al. (2018). Pregnancy outcome following in utero exposure to azathioprine: a French comparative observational study. Therapie, 73:199–207. 10.1016/j.therap.2017.06.006 [PubMed] [CrossRef] [Google Scholar]

    Armenti, V.T., Moritz, M.J., Davison, J.M. (2013). Breastfeeding and tacrolimus: is it a reasonable approach? Expert Rev Clin Immunol, 9:623–6. 10.1586/1744666X.2013.811042 [PubMed] [CrossRef] [Google Scholar]

    Asghar, H., Sheikh, F.N., Dev, H., Lazarevic, M.B., Hassan, S.A. (2019). An atypical presentation of myasthenia gravis: A Case Report. Cureus, 11(4): e4563. doi: 10.7759/cureus.4563

    Barraud, C., Desguerre, I., Barnerias, C., Gitiaux, C., Boulay, C., Chabrol, B. (2018). Clinical features and evolution of juvenile myasthenia gravis in a French cohort. Muscle Nerve, 57:603–9. 10.1002/mus.25965 [PubMed] [CrossRef] [Google Scholar]

    Barth, D., Nabavi, N.M., Ng, E., Nwe, P., Bril, V. (2011) . Comparison of IVIg and PLEX in patients with myasthenia gravis. Neurology, 76:2017–23. 10.1212/WNL.0b013e31821e5505 [PMC free article] [PubMed] [CrossRef] [Google Scholar]

    Berrih, A.S. (2016). Role of the thymus in autoimmune myasthenia gravis. Clin Exp Neuroimmunol, 7:226–37. 10.1111/cen3.12319 [CrossRef] [Google Scholar]

    Buzzard, K.A., Meyer, N.J., Hardy, T.A., Riminton, D.S., Reddel, S.W. (2015). Induction intravenous cyclophosphamide followed by maintenance oral immunosuppression in refractory myasthenia gravis. Muscle Nerve, 52:204–10. 10.1002/mus.24536 [PubMed] [CrossRef] [Google Scholar]

    Castro, D., Derisavifard, S., Anderson, M., Greene, M., Iannaccone, S. (2013). Juvenile myasthenia gravis: a twenty-year experience. J Clin Neuromuscul Dis, 14:95–102. 10.1097/CND.0b013e318253a48e [PubMed] [CrossRef] [Google Scholar]

    Chang, C.C., Lin, T.M., Chang, Y.S., Chen, W.S., Sheu, J.J., Chen, Y.H., et al. (2019). Thymectomy in patients with myasthenia gravis increases the risk of autoimmune rheumatic diseases: a nationwide cohort study. Rheumatology, 58:135–43. 10.1093/rheumatology/key236 [PubMed] [CrossRef] [Google Scholar]

    Chou, C.C., Su, I.C., Chou, I.J., Lin, J.J., Lan, S.Y, Wang, Y.S., et al. (2019). Correlation of anti-acetylcholine receptor antibody levels and long-term outcomes of juvenile myasthenia gravis in Taiwan: a case control study. BMC Neurol, 19:170. 10.1186/s12883-019-1397-0 [PMC free article] [PubMed] [CrossRef] [Google Scholar]

    Connell, K.O., Ramdas, S., Palace, J. (2020). Management of juvenile myasthenia gravis. Front Neurol , 11:743. doi: 10.3389/fneur.2020.00743

    Coscia, L.A., Armenti, D.P., King, R.W., Sifontis, N.M., Constantinescu, S., Moritz, M.J. (2015). Update on the teratogenicity of maternal mycophenolate mofetil. J Pediatr Genet, 4:42–55. 10.1055/s-0035-1556743 [PMC free article] [PubMed] [CrossRef] [Google Scholar]

    Cruz, J.L., Wolff, M.L., Vanderman, A.J., Brown, J.N. (2015). The emerging role of tacrolimus in myasthenia gravis. Ther Adv Neurol Disord, 8:92–103. 10.1177/1756285615571873 [PMC free article] [PubMed] [CrossRef] [Google Scholar]

    Europa, T.A., Nel, M., Heckmann, J.M. (2018). Myasthenic ophthalmoparesis: time to resolution after initiating immune therapies. Muscle Nerve, 58:542–9. 10.1002/mus.26172 [PubMed] [CrossRef] [Google Scholar]

    Evoli, A., Alboini, P.E., Damato, V., Iorio, R., Provenzano, C., Bartoccioni, E., et al. (2018). Myasthenia gravis with antibodies to MuSK: an update. Ann N Y Acad Sci, 1412:82–89. 10.1111/nyas.13518 [PubMed] [CrossRef] [Google Scholar]

    Finnis, M.F., Jayawant, S. (2011). Juvenile myasthenia gravis: a paediatric perspective. Autoimmune Dis, 2011:404101. 10.4061/2011/404101 [PMC free article] [PubMed] [CrossRef] [Google Scholar]

    Fisher, K., & Shah, V. (2019). Pediatric ocular myasthenia gravis. Curr Treat Options Neurol, 26;21(10):46. doi: 10.1007/s11940-019-0593-y

    Gilhus, N.E., Owe, J.F., Hoff, J.M., Romi, F., Skeie, G.O., Aarli, J.A. (2011). Myasthenia gravis: a review of available treatment approaches. Autoimmune Dis, 2011:847393. [PMC free article] [PubMed]

    Gilhus, N.E., Tzartos, S., Evoli, A., Palace, J., Burns, T.M., Verschuuren, J. (2019). Myasthenia gravis. Nat Rev Dis Primers, 5:30 10.1038/s41572-019-0079-y [PubMed] [CrossRef] [Google Scholar]

    Gomez, F.E., Garcia, T.S., Bazan, R.L., Cervantes, U.R., Chac, L.G., Lopez, H.J.C., et al. (2020). Intravenous cyclophosphamide monthly pulses in refractory myasthenia gravis. J Neuro, 267:674–8. 10.1007/s00415-019-09622-4 [PubMed] [CrossRef] [Google Scholar]

    Govindarajan, R., Iyadurai, S.J., Connolly, A., Zaidman, C. (2015). Selective response to rituximab in a young child with MuSK-associated myasthenia gravis. Neuromuscul Disord, 25:651–2. 10.1016/j.nmd.2015.03.014 [PubMed] [CrossRef] [Google Scholar]

    Gui, M., Luo, X., Lin, J., Li, Y., Zhang, M., Zhang, X., et al. (2015) . Long-term outcome of 424 childhood-onset myasthenia gravis patients. J Neurol, 262:823–30. 10.1007/s00415-015-7638-2 [PubMed] [CrossRef] [Google Scholar]

    Guptill, J.T., Sanders, D.B., Evoli, A. (2011). Anti-MuSK antibody myasthenia gravis: clinical findings and response to treatment in two large cohorts. Muscle Nerve, 44:36–40. 10.1002/mus.22006 [PubMed] [CrossRef] [Google Scholar]

    Hacohen, Y., Jacobson, L.W., Byrne, S., Norwood, F., Lall, A., Robb, S., et al. (2015). Fetal acetylcholine receptor inactivation syndrome: a myopathy due to maternal antibodies. Neurol Neuroimmunol Neuroinflamm, 2:e57. 10.1212/NXI.0000000000000057 [PMC free article] [PubMed] [CrossRef] [Google Scholar]

    Hamel, J., Ciafaloni, E. (2018). An update: myasthenia gravis and pregnancy. Neurol Clin, 36:355–65. 10.1016/j.ncl.2018.01.005 [PubMed] [CrossRef] [Google Scholar]

    Heckmann, J.M., Hansen, P., Van, T.R., Lubbe, E., Janse, V.R.E., Wilmshurst, J.M. (2012). The characteristics of juvenile myasthenia gravis among South Africans. S Afr Med J, 102:532–6. 10.7196/SAMJ.5390 [PubMed] [CrossRef] [Google Scholar]

    Huang, X., Li, Y., Feng, H., Chen, P., Liu, W. (2018). Clinical characteristics of juvenile myasthenia gravis in southern China. Front Neurol, 9:77. 10.3389/fneur.2018.00077 [PMC free article] [PubMed] [CrossRef] [Google Scholar]

    Huang, X., Liu, W.B., Men, L.N., Feng, H.Y., Li, Y., Luo, C.M., et al. (2013). Clinical features of myasthenia gravis in southern China: a retrospective review of 2,154 cases over 22 years. Neurol Sci, 34:911–7. 10.1007/s10072-012-1157-z [PubMed] [CrossRef] [Google Scholar]

    Kaegi, C., Wuest, B., Schreiner, J., Steiner, U.C., Vultaggio, A., Matucci, A., et al. (2019). Systematic review of safety and efficacy of rituximab in treating immune-mediated disorders. Front Immunol, 10:1990. 10.3389/fimmu.2019.01990 [PMC free article] [PubMed] [CrossRef] [Google Scholar]

    Koul, R., Al-Futaisi, A., Abdelrahim, R., Mani, R., Abdwani, R., Al-Asmi, A. (2018). Rituximab treatment in myasthaenia gravis: report of two paediatric cases. Sultan Qaboos Univ Med J, 18:e223–7. 10.18295/squmj.2018.18.02.018 [PMC free article] [PubMed] [CrossRef] [Google Scholar]

    Lee, H.N., Kang, H.C., Lee, J.S, Kim, H.D., Shin, H.Y., Kim, S.M., et al. (2016). Juvenile myasthenia gravis in Korea: subgroup analysis according to sex and onset age. J Child Neurol, 31:1561–8. 10.1177/0883073816666206 [PubMed] [CrossRef] [Google Scholar]

    Li, L., Xiong, W.C., Mei, L. (2018). Neuromuscular junction formation, aging, and disorders. Annu Rev Physiol, 10;80:159-188. [PubMed]

    Liew, W.K., Powell, C.A., Sloan, S.R., Shamberger, R.C., Weldon, C.B., Darras, B.T., et al. . (2014). Comparison of plasmapheresis and intravenous immunoglobulin as maintenance therapies for juvenile myasthenia gravis. JAMA Neurol, 71:575–80. 10.1001/jamaneurol.2014.17 [PubMed] [CrossRef] [Google Scholar]

    Madenci, A.L., Li, G.Z., Weil, B.R., Zurakowski, D., Kang, P.B., Weldon, C.B. (2017). The role of thymectomy in the treatment of juvenile myasthenia gravis: a systematic review. Pediatr Surg Int, 33:683–94. 10.1007/s00383-017-4086-3 [PubMed] [CrossRef] [Google Scholar]

    Mansukhani, S.A., Bothun, E.D., Diehl, N.N., Mohney, B.G. (2019). Incidence and ocular features of pediatric myasthenias. Am J Ophthalmol, 200:242–9. 10.1016/j.ajo.2019.01.004 [PMC free article] [PubMed] [CrossRef] [Google Scholar]

    Mehndiratta, M.M., Pandey, S., Kuntzer, T. (2014). Acetylcholinesterase inhibitor treatment for myasthenia gravis. Cochrane Database Syst Rev, 13:CD006986 10.1002/14651858.CD006986.pub3 [PMC free article] [PubMed] [CrossRef] [Google Scholar]

    Mombaur, B., Lesosky, M.R., Liebenberg, L., Vreede, H., Heckmann, J.M. (2015). Incidence of acetylcholine receptor-antibody-positive myasthenia gravis in South Africa. Muscle Nerve, 51:533–7. 10.1002/mus.24348 [PubMed] [CrossRef] [Google Scholar]

    Mori, T., Mori, K., Suzue, M., Ito, H., Kagami, S. (2013). Effective treatment of a 13-year-old boy with steroid-dependent ocular myasthenia gravis using tacrolimus. Brain Dev, 35:445–8. 10.1016/j.braindev.2012.06.012 [PubMed] [CrossRef] [Google Scholar]

    Munot, P., Robb, S.A., Niks, E.H., Palace, J., EWSC workshop study group. (2020). 242nd ENMC international diagnosis and management of juvenile myasthenia gravis Hoofddorp, the Netherlands, 1-3 March 2019. Neuromuscul Disord, 30:254–64. 10.1016/j.nmd.2020.02.001 [PubMed] [CrossRef] [Google Scholar]

    Murai, H., Yamashita, N., Watanabe, M., Nomura, Y., Motomura, M., Yoshikawa, H., et al. (2011). Characteristics of myasthenia gravis according to onset-age: Japanese nationwide survey. J Neurol Sci, 305:97–102. 10.1016/j.jns.2011.03.004 [PubMed] [CrossRef] [Google Scholar]

    Murthy, J.M.K. (2020). Myasthenia gravis: Do the subtypes matter?. Ann Indian Acad Neurol, Jan-Feb;23(1):2. [PMC free article] [PubMed]

    Parr, J. R., Andrew, M.J., Finnis, M., Beeson, D., Vincent, A., Jayawant, S. (2014). How common is childhood myasthenia? The UK incidence and prevalence of autoimmune and congenital myasthenia. Arch Dis Child, 99:539–42. 10.1136/archdischild-2013-304788 [PubMed] [CrossRef] [Google Scholar]

    Pedersen, E.G., Hallas, J., Hansen, K., Jensen, P.E., Gaist, D. (2013). Late-onset myasthenia not on the increase: a nationwide register study in Denmark, 1996–2009. Eur J Neurol, 20:309–14. 10.1111/j.1468-1331.2012.03850.x [PubMed] [CrossRef] [Google Scholar]

    Pitt, M.C. (2017). Use of stimulated electromyography in the analysis of the neuromuscular junction in children. Muscle Nerve, 56:841–7. 10.1002/mus.25685 [PubMed] [CrossRef] [Google Scholar]

    Pitt, M.C., McHugh, J.C., Deeb, J., Smith, R.A. (2017). Assessing neuromuscular junction stability from stimulated EMG in children. Clin Neurophysiol, 128:290–6. 10.1016/j.clinph.2016.11.020 [PubMed] [CrossRef] [Google Scholar]

    Popperud, T.H., Boldingh, M.I., Brunborg, C., Faiz, K.W., Heldal, A.T., Maniaol, A.H., et al. (2017) . Juvenile myasthenia gravis in Norway: a nationwide epidemiological study. Eur J Paediatr Neurol, 21:312–17. 10.1016/j.ejpn.2016.09.001 [PubMed] [CrossRef] [Google Scholar]

    Reeves, H.M., Winters, J.L. (2014). The mechanisms of action of plasma exchange. Br J Haematol, 164:342–51. 10.1111/bjh.12629 [PubMed] [CrossRef] [Google Scholar]

    Skjei, K.L., Lennon, V.A., Kuntz, N.L. (2013) . Muscle specific kinase autoimmune myasthenia gravis in children: a case series. Neuromuscul Disord, 23:874–82. 10.1016/j.nmd.2013.07.010 [PubMed] [CrossRef] [Google Scholar]

    Suresh, A.B., & Asuncion, R.M.D. (2021). Myasthenia gravis. StatPearls [Internet]. https://www.ncbi.nlm.nih.gov/books/NBK559331/

    Tozawa, T., Nishimura, A., Ueno, T., Kaneda, D., Miyanomae, Y., Chiyonobu, T., et al. (2018). A 5-Year follow-up of triple-seronegative myasthenia gravis successfully treated with tacrolimus therapy. Neuropediatrics, 49:200–3. 10.1055/s-0037-1618591 [PubMed] [CrossRef] [Google Scholar]

    Vanikieti, K., Lowwongngam, K., Padungkiatsagul, T., Visudtibhan, A., Poonyathalang, A. (2018). Juvenile ocular myasthenia gravis: Presentation and outcome of a large cohort. Pediatr Neurol, 87:36-41. doi: 10.1016/j.pediatrneurol.2018.06.007

    Vecchio, D., Ramdas, S., Munot, P., Pitt, M., Beeson, D., Knight, R., et al. (2020). Paediatric myasthenia gravis: prognostic factors for drug free remission. Neuromuscul Disord, 30:120–7. 10.1016/j.nmd.2019.11.008 [PubMed] [CrossRef] [Google Scholar]

    Weger, S., Appendino, J.P., Clark, I.H. (2019). Longstanding and refractory anti-muscle specific tyrosine kinase antibody-associated myasthenia gravis (Anti-MuSK-MG) in a child successfully treated with rituximab. J Binocul Vis Ocul Motil, 69:26–29. 10.1080/2576117X.2019.1578164 [PubMed] [CrossRef] [Google Scholar].

  1. Alami, Z., Agier, M.S., Ahid, S., Vial, T., Dautriche, A., Lagarce, L., et al. (2018). Pregnancy outcome following in utero exposure to azathioprine: a French comparative observational study. Therapie, 73:199–207. 10.1016/j.therap.2017.06.006 [PubMed] [CrossRef] [Google Scholar]
  2. Armenti, V.T., Moritz, M.J., Davison, J.M. (2013). Breastfeeding and tacrolimus: is it a reasonable approach? Expert Rev Clin Immunol, 9:623–6. 10.1586/1744666X.2013.811042 [PubMed] [CrossRef] [Google Scholar]
  3. Asghar, H., Sheikh, F.N., Dev, H., Lazarevic, M.B., Hassan, S.A. (2019). An atypical presentation of myasthenia gravis: A Case Report. Cureus, 11(4): e4563. doi: 10.7759/cureus.4563
  4. Barraud, C., Desguerre, I., Barnerias, C., Gitiaux, C., Boulay, C., Chabrol, B. (2018). Clinical features and evolution of juvenile myasthenia gravis in a French cohort. Muscle Nerve, 57:603–9. 10.1002/mus.25965 [PubMed] [CrossRef] [Google Scholar]
  5. Barth, D., Nabavi, N.M., Ng, E., Nwe, P., Bril, V. (2011) . Comparison of IVIg and PLEX in patients with myasthenia gravis. Neurology, 76:2017–23. 10.1212/WNL.0b013e31821e5505 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
  6. Berrih, A.S. (2016). Role of the thymus in autoimmune myasthenia gravis. Clin Exp Neuroimmunol, 7:226–37. 10.1111/cen3.12319 [CrossRef] [Google Scholar]
  7. Buzzard, K.A., Meyer, N.J., Hardy, T.A., Riminton, D.S., Reddel, S.W. (2015). Induction intravenous cyclophosphamide followed by maintenance oral immunosuppression in refractory myasthenia gravis. Muscle Nerve, 52:204–10. 10.1002/mus.24536 [PubMed] [CrossRef] [Google Scholar]
  8. Castro, D., Derisavifard, S., Anderson, M., Greene, M., Iannaccone, S. (2013). Juvenile myasthenia gravis: a twenty-year experience. J Clin Neuromuscul Dis, 14:95–102. 10.1097/CND.0b013e318253a48e [PubMed] [CrossRef] [Google Scholar]
  9. Chang, C.C., Lin, T.M., Chang, Y.S., Chen, W.S., Sheu, J.J., Chen, Y.H., et al. (2019). Thymectomy in patients with myasthenia gravis increases the risk of autoimmune rheumatic diseases: a nationwide cohort study. Rheumatology, 58:135–43. 10.1093/rheumatology/key236 [PubMed] [CrossRef] [Google Scholar]
  10. Chou, C.C., Su, I.C., Chou, I.J., Lin, J.J., Lan, S.Y, Wang, Y.S., et al. (2019). Correlation of anti-acetylcholine receptor antibody levels and long-term outcomes of juvenile myasthenia gravis in Taiwan: a case control study. BMC Neurol, 19:170. 10.1186/s12883-019-1397-0 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
  11. Connell, K.O., Ramdas, S., Palace, J. (2020). Management of juvenile myasthenia gravis. Front Neurol , 11:743. doi: 10.3389/fneur.2020.00743
  12. Coscia, L.A., Armenti, D.P., King, R.W., Sifontis, N.M., Constantinescu, S., Moritz, M.J. (2015). Update on the teratogenicity of maternal mycophenolate mofetil. J Pediatr Genet, 4:42–55. 10.1055/s-0035-1556743 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
  13. Cruz, J.L., Wolff, M.L., Vanderman, A.J., Brown, J.N. (2015). The emerging role of tacrolimus in myasthenia gravis. Ther Adv Neurol Disord, 8:92–103. 10.1177/1756285615571873 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
  14. Europa, T.A., Nel, M., Heckmann, J.M. (2018). Myasthenic ophthalmoparesis: time to resolution after initiating immune therapies. Muscle Nerve, 58:542–9. 10.1002/mus.26172 [PubMed] [CrossRef] [Google Scholar]
  15. Evoli, A., Alboini, P.E., Damato, V., Iorio, R., Provenzano, C., Bartoccioni, E., et al. (2018). Myasthenia gravis with antibodies to MuSK: an update. Ann N Y Acad Sci, 1412:82–89. 10.1111/nyas.13518 [PubMed] [CrossRef] [Google Scholar]
  16. Finnis, M.F., Jayawant, S. (2011). Juvenile myasthenia gravis: a paediatric perspective. Autoimmune Dis, 2011:404101. 10.4061/2011/404101 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
  17. Fisher, K., & Shah, V. (2019). Pediatric ocular myasthenia gravis. Curr Treat Options Neurol, 26;21(10):46. doi: 10.1007/s11940-019-0593-y
  18. Gilhus, N.E., Owe, J.F., Hoff, J.M., Romi, F., Skeie, G.O., Aarli, J.A. (2011). Myasthenia gravis: a review of available treatment approaches. Autoimmune Dis, 2011:847393. [PMC free article] [PubMed]
  19. Gilhus, N.E., Tzartos, S., Evoli, A., Palace, J., Burns, T.M., Verschuuren, J. (2019). Myasthenia gravis. Nat Rev Dis Primers, 5:30 10.1038/s41572-019-0079-y [PubMed] [CrossRef] [Google Scholar]
  20. Gomez, F.E., Garcia, T.S., Bazan, R.L., Cervantes, U.R., Chac, L.G., Lopez, H.J.C., et al. (2020). Intravenous cyclophosphamide monthly pulses in refractory myasthenia gravis. J Neuro, 267:674–8. 10.1007/s00415-019-09622-4 [PubMed] [CrossRef] [Google Scholar]
  21. Govindarajan, R., Iyadurai, S.J., Connolly, A., Zaidman, C. (2015). Selective response to rituximab in a young child with MuSK-associated myasthenia gravis. Neuromuscul Disord, 25:651–2. 10.1016/j.nmd.2015.03.014 [PubMed] [CrossRef] [Google Scholar]
  22. Gui, M., Luo, X., Lin, J., Li, Y., Zhang, M., Zhang, X., et al. (2015) . Long-term outcome of 424 childhood-onset myasthenia gravis patients. J Neurol, 262:823–30. 10.1007/s00415-015-7638-2 [PubMed] [CrossRef] [Google Scholar]
  23. Guptill, J.T., Sanders, D.B., Evoli, A. (2011). Anti-MuSK antibody myasthenia gravis: clinical findings and response to treatment in two large cohorts. Muscle Nerve, 44:36–40. 10.1002/mus.22006 [PubMed] [CrossRef] [Google Scholar]
  24. Hacohen, Y., Jacobson, L.W., Byrne, S., Norwood, F., Lall, A., Robb, S., et al. (2015). Fetal acetylcholine receptor inactivation syndrome: a myopathy due to maternal antibodies. Neurol Neuroimmunol Neuroinflamm, 2:e57. 10.1212/NXI.0000000000000057 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
  25. Hamel, J., Ciafaloni, E. (2018). An update: myasthenia gravis and pregnancy. Neurol Clin, 36:355–65. 10.1016/j.ncl.2018.01.005 [PubMed] [CrossRef] [Google Scholar]
  26. Heckmann, J.M., Hansen, P., Van, T.R., Lubbe, E., Janse, V.R.E., Wilmshurst, J.M. (2012). The characteristics of juvenile myasthenia gravis among South Africans. S Afr Med J, 102:532–6. 10.7196/SAMJ.5390 [PubMed] [CrossRef] [Google Scholar]
  27. Huang, X., Li, Y., Feng, H., Chen, P., Liu, W. (2018). Clinical characteristics of juvenile myasthenia gravis in southern China. Front Neurol, 9:77. 10.3389/fneur.2018.00077 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
  28. Huang, X., Liu, W.B., Men, L.N., Feng, H.Y., Li, Y., Luo, C.M., et al. (2013). Clinical features of myasthenia gravis in southern China: a retrospective review of 2,154 cases over 22 years. Neurol Sci, 34:911–7. 10.1007/s10072-012-1157-z [PubMed] [CrossRef] [Google Scholar]
  29. Kaegi, C., Wuest, B., Schreiner, J., Steiner, U.C., Vultaggio, A., Matucci, A., et al. (2019). Systematic review of safety and efficacy of rituximab in treating immune-mediated disorders. Front Immunol, 10:1990. 10.3389/fimmu.2019.01990 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
  30. Koul, R., Al-Futaisi, A., Abdelrahim, R., Mani, R., Abdwani, R., Al-Asmi, A. (2018). Rituximab treatment in myasthaenia gravis: report of two paediatric cases. Sultan Qaboos Univ Med J, 18:e223–7. 10.18295/squmj.2018.18.02.018 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
  31. Lee, H.N., Kang, H.C., Lee, J.S, Kim, H.D., Shin, H.Y., Kim, S.M., et al. (2016). Juvenile myasthenia gravis in Korea: subgroup analysis according to sex and onset age. J Child Neurol, 31:1561–8. 10.1177/0883073816666206 [PubMed] [CrossRef] [Google Scholar]
  32. Li, L., Xiong, W.C., Mei, L. (2018). Neuromuscular junction formation, aging, and disorders. Annu Rev Physiol, 10;80:159-188. [PubMed]
  33. Liew, W.K., Powell, C.A., Sloan, S.R., Shamberger, R.C., Weldon, C.B., Darras, B.T., et al. . (2014). Comparison of plasmapheresis and intravenous immunoglobulin as maintenance therapies for juvenile myasthenia gravis. JAMA Neurol, 71:575–80. 10.1001/jamaneurol.2014.17 [PubMed] [CrossRef] [Google Scholar]
  34. Madenci, A.L., Li, G.Z., Weil, B.R., Zurakowski, D., Kang, P.B., Weldon, C.B. (2017). The role of thymectomy in the treatment of juvenile myasthenia gravis: a systematic review. Pediatr Surg Int, 33:683–94. 10.1007/s00383-017-4086-3 [PubMed] [CrossRef] [Google Scholar]
  35. Mansukhani, S.A., Bothun, E.D., Diehl, N.N., Mohney, B.G. (2019). Incidence and ocular features of pediatric myasthenias. Am J Ophthalmol, 200:242–9. 10.1016/j.ajo.2019.01.004 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
  36. Mehndiratta, M.M., Pandey, S., Kuntzer, T. (2014). Acetylcholinesterase inhibitor treatment for myasthenia gravis. Cochrane Database Syst Rev, 13:CD006986 10.1002/14651858.CD006986.pub3 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
  37. Mombaur, B., Lesosky, M.R., Liebenberg, L., Vreede, H., Heckmann, J.M. (2015). Incidence of acetylcholine receptor-antibody-positive myasthenia gravis in South Africa. Muscle Nerve, 51:533–7. 10.1002/mus.24348 [PubMed] [CrossRef] [Google Scholar]
  38. Mori, T., Mori, K., Suzue, M., Ito, H., Kagami, S. (2013). Effective treatment of a 13-year-old boy with steroid-dependent ocular myasthenia gravis using tacrolimus. Brain Dev, 35:445–8. 10.1016/j.braindev.2012.06.012 [PubMed] [CrossRef] [Google Scholar]
  39. Munot, P., Robb, S.A., Niks, E.H., Palace, J., EWSC workshop study group. (2020). 242nd ENMC international diagnosis and management of juvenile myasthenia gravis Hoofddorp, the Netherlands, 1-3 March 2019. Neuromuscul Disord, 30:254–64. 10.1016/j.nmd.2020.02.001 [PubMed] [CrossRef] [Google Scholar]
  40. Murai, H., Yamashita, N., Watanabe, M., Nomura, Y., Motomura, M., Yoshikawa, H., et al. (2011). Characteristics of myasthenia gravis according to onset-age: Japanese nationwide survey. J Neurol Sci, 305:97–102. 10.1016/j.jns.2011.03.004 [PubMed] [CrossRef] [Google Scholar]
  41. Murthy, J.M.K. (2020). Myasthenia gravis: Do the subtypes matter?. Ann Indian Acad Neurol, Jan-Feb;23(1):2. [PMC free article] [PubMed]
  42. Parr, J. R., Andrew, M.J., Finnis, M., Beeson, D., Vincent, A., Jayawant, S. (2014). How common is childhood myasthenia? The UK incidence and prevalence of autoimmune and congenital myasthenia. Arch Dis Child, 99:539–42. 10.1136/archdischild-2013-304788 [PubMed] [CrossRef] [Google Scholar]
  43. Pedersen, E.G., Hallas, J., Hansen, K., Jensen, P.E., Gaist, D. (2013). Late-onset myasthenia not on the increase: a nationwide register study in Denmark, 1996–2009. Eur J Neurol, 20:309–14. 10.1111/j.1468-1331.2012.03850.x [PubMed] [CrossRef] [Google Scholar]
  44. Pitt, M.C. (2017). Use of stimulated electromyography in the analysis of the neuromuscular junction in children. Muscle Nerve, 56:841–7. 10.1002/mus.25685 [PubMed] [CrossRef] [Google Scholar]
  45. Pitt, M.C., McHugh, J.C., Deeb, J., Smith, R.A. (2017). Assessing neuromuscular junction stability from stimulated EMG in children. Clin Neurophysiol, 128:290–6. 10.1016/j.clinph.2016.11.020 [PubMed] [CrossRef] [Google Scholar]
  46. Popperud, T.H., Boldingh, M.I., Brunborg, C., Faiz, K.W., Heldal, A.T., Maniaol, A.H., et al. (2017) . Juvenile myasthenia gravis in Norway: a nationwide epidemiological study. Eur J Paediatr Neurol, 21:312–17. 10.1016/j.ejpn.2016.09.001 [PubMed] [CrossRef] [Google Scholar]
  47. Reeves, H.M., Winters, J.L. (2014). The mechanisms of action of plasma exchange. Br J Haematol, 164:342–51. 10.1111/bjh.12629 [PubMed] [CrossRef] [Google Scholar]
  48. Skjei, K.L., Lennon, V.A., Kuntz, N.L. (2013) . Muscle specific kinase autoimmune myasthenia gravis in children: a case series. Neuromuscul Disord, 23:874–82. 10.1016/j.nmd.2013.07.010 [PubMed] [CrossRef] [Google Scholar]
  49. Suresh, A.B., & Asuncion, R.M.D. (2021). Myasthenia gravis. StatPearls [Internet]. https://www.ncbi.nlm.nih.gov/books/NBK559331/
  50. Tozawa, T., Nishimura, A., Ueno, T., Kaneda, D., Miyanomae, Y., Chiyonobu, T., et al. (2018). A 5-Year follow-up of triple-seronegative myasthenia gravis successfully treated with tacrolimus therapy. Neuropediatrics, 49:200–3. 10.1055/s-0037-1618591 [PubMed] [CrossRef] [Google Scholar]
  51. Vanikieti, K., Lowwongngam, K., Padungkiatsagul, T., Visudtibhan, A., Poonyathalang, A. (2018). Juvenile ocular myasthenia gravis: Presentation and outcome of a large cohort. Pediatr Neurol, 87:36-41. doi: 10.1016/j.pediatrneurol.2018.06.007
  52. Vecchio, D., Ramdas, S., Munot, P., Pitt, M., Beeson, D., Knight, R., et al. (2020). Paediatric myasthenia gravis: prognostic factors for drug free remission. Neuromuscul Disord, 30:120–7. 10.1016/j.nmd.2019.11.008 [PubMed] [CrossRef] [Google Scholar]
  53. Weger, S., Appendino, J.P., Clark, I.H. (2019). Longstanding and refractory anti-muscle specific tyrosine kinase antibody-associated myasthenia gravis (Anti-MuSK-MG) in a child successfully treated with rituximab. J Binocul Vis Ocul Motil, 69:26–29. 10.1080/2576117X.2019.1578164 [PubMed] [CrossRef] [Google Scholar].